ALT Altimmune Inc

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune to Participate in Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:

  • Stifel 2025 Healthcare Conference

    Wednesday, November 12, 2025

    Fireside Chat at 10:00 a.m. ET
  • Jefferies Global Healthcare Conference

    Thursday, November 20, 2025

    Fireside Chat at 9:30 a.m. GMT

The sessions will be webcast and can be accessed by visiting the section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

Media Contact:

Elliot Fox

Real Chemistry

This press release was published by a CLEAR® Verified individual.



EN
05/11/2025

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune to Participate in Two Upcoming Investor Conferences GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences: Stifel 2025 Healthcare ConferenceWednesday, November 12, 2025Fireside Chat at 10:00 a.m. ET Jefferies Global Healthcare ConferenceThursday, November 20, 2025Fireside Chat ...

8h / 37m 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 ...

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026 GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the completion of patient enroll...

November 3, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Report Third Quarter 2025 Financial Results and Provide B...

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025. Altimmune management will host a conference call at 8:30 a.m. ET on November 6 to discuss financial results and provide a business update. The conference call will be webcast live ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in La...

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025 Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that 24-week data from its Phase 2b IMPACT trial of pemvidutide in metab...

October 20, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD...

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide  Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appoint...

September 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch